A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepressant-resistant major depression or patients with dysthymic disorder [Estudio de Fase II, piloto, prospectivo, randomizado, doble ciego, de 12 semanas de duración para comparar la eficacia y seguridad de masitinib frente a placebo en el tratamiento de trastornos del estado de ánimo en pacientes con depresión mayor resistente a los antidepresivos o en pacientes con trastornos distímicos.]
Latest Information Update: 29 May 2018
At a glance
- Drugs Masitinib (Primary)
- Indications Dysthymic disorder; Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- 24 May 2018 Status changed from recruiting to discontinued.
- 06 Aug 2013 New trial record